Roivant Sciences Ltd Financials

Market Capitalization £None as of Jan. 11, 2021

Valuations Metrics as of May. 5, 2024

Trailing PE	2.09
Forward PE	-8.29
Price to Sales TTM	$72.12
Price to Book MRQ	$1.46
Enterprise to Revenue	26.12
Enterprise to EBITDA	-3.14

Financial Reports as of Dec. 31, 2023

Financials

Fiscal Year Ends	2023-03-31
Most Recent Quarter	2023-12-31
Profit Margin	3624.14%
Operating Margin	-774.17%
Return on Assets TTM	-13.77%
Return on Equity TTM	105.80%

Income Statement

Revenue TTM	$123,241,000
Revenue per Share TTM	$0.16
Quarterly Revenue Growth	117.80%
Gross Profit TTM	$48,152,000
EBITDA	$-1,025,345,984
Net Income to Common TTM	$4,351,862,784
Diluted EPS TTM	$5.27
Quarterly Earnings Growth YoY	%

Balance Sheet

Total Cash MRQ	$6,670,810,112
Total Cash per Share MRQ	$8.28
Total Debt MRQ	$
Total Debt to Equity MRQ	7.69
Current Ratio MRQ	27.79
Book Value per Share MRQ	$7.57

Cash Flow

Operating Cash Flow TTM	$-835,899,008
Levered Free Cash Flow TTM	$-502,471,008

ROIV Stock Info as of May. 5, 2024

Stock Statistics

Shares Outstanding	805,846,016
Float Shares	421,642,806
Avg 10 Volume	4,186,920
Avg 30 Volume	None
Shares Short	45,129,442
Short Ratio	4.05
Short % of Shares	10.50%
% Held by Insiders	20.62%
% Held by Institutions	62.56%

Stock Price Summary

Beta	1.34
Fifty Two Week Low	$8.25
Fifty Two Week High	$13.24
Fifty Two Week Change	21.34%
Day 50 MA	$10.94
Day 200 MA	$10.64

Dividends and Splits

Forward Annual Dividend Rate	$
Forward Annual Dividend Yield	%
Trailing Annual Dividend Rate	$0.00
Trailing Annual Dividend Yield	0.00%
Payout Ratio	0.00%
Dividend Date
Ex Dividend Date
Last Split Factor
Last Split Date